Literature DB >> 2535956

Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells.

T K Lee1, R D Horner, J F Silverman, Y H Chen, C Jenny, C W Scarantino.   

Abstract

This study evaluated data from 30 non-small cell lung cancer (NSCLC) patients to determine whether demographic, clinical, and morphologic and morphometric data that were obtained prior to treatment, could be used to predict survival. All patients had Stage III disease, and all subsequently were treated identically with concurrent radiotherapy, cisplatin, and 5-fluorouracil. The series consisted of 18 squamous carcinomas, eight adenocarcinomas, and four large cell carcinomas. Morphometric measurements of randomized selected cancer cells per case included diameter of cytoplasm, nuclei, and nucleoli. Morphologic parameters evaluated were mitotic index, histologic differentiation, and pattern of nuclear chromatin of cancer cells, and the degree of necrosis and fibrosis of tumor tissue. The lymphoid and neutrophil index defined as the ratio of lymphoid cells and neutrophils to cancer cells from randomized microscopic fields (median = 25) at 400 x magnification were also determined. Our study indicated that the peritumor lymphoid index was the only factor significantly associated with the length of survival. The correlation coefficient (Pearson r) of these two factors was 0.5 (P less than 0.005). The median survival time of patients with peritumor lymphoid index less than 3 and greater than or equal to 3 was 95 days and 376 days, respectively (Kaplan-Meier estimation). The peritumor lymphoid index was an independent prognosticator of clinical outcome of Stage III NSCLC patients, and did not correlate with any of the other parameters analyzed.

Entities:  

Mesh:

Year:  1989        PMID: 2535956     DOI: 10.1002/1097-0142(19890115)63:2<309::aid-cncr2820630218>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Pleural Neutrophil-to-Lymphocyte Ratio May Be Associated With Early Disease Progression in Stage IV Non-small Cell Lung Cancer.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hyung Woo Kim; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome.

Authors:  A Bellocq; M Antoine; A Flahault; C Philippe; B Crestani; J F Bernaudin; C Mayaud; B Milleron; L Baud; J Cadranel
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

3.  Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma.

Authors:  M Wislez; J Fleury-Feith; N Rabbe; J Moreau; D Cesari; B Milleron; C Mayaud; M Antoine; P Soler; J Cadranel
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

Review 4.  Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review.

Authors:  Charalampos Gkogkou; Konstantina Frangia; Muhammad W Saif; Rodoula Trigidou; Konstantinos Syrigos
Journal:  Springerplus       Date:  2014-03-01

5.  Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma.

Authors:  Dongxian Jiang; Yalan Liu; Hao Wang; Haixing Wang; Qi Song; Akesu Sujie; Jie Huang; Yifan Xu; Haiying Zeng; Lijie Tan; Yingyong Hou; Chen Xu
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

6.  Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Hye Seon Kang; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

7.  Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study.

Authors:  Jeong Uk Lim; Hye Seon Kang; Chang Dong Yeo; Ju Sang Kim; Chan Kwon Park; Yong Hyun Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-12-14

8.  Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.

Authors:  Wen Feng; Yuan Li; Lei Shen; Xu-Wei Cai; Zheng-Fei Zhu; Jian-Hua Chang; Jia-Qing Xiang; Ya-Wei Zhang; Hai-Quan Chen; Xiao-Long Fu
Journal:  Oncotarget       Date:  2016-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.